Login to Your Account

Janssen tie vouches for Protagonist, pledges up to $990M in IBD

By Randy Osborne
Staff Writer

Tuesday, May 30, 2017

In what CEO Dinesh Patel called a “front-end-loaded deal that is significant from now through successful completion of phase II trials,” Protagonist Therapeutics Inc. sealed a deal potentially worth $990 million with Janssen Biotech Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription